Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
What immunosuppression regimens do clinicians use in patients with progressive RB-ILD despite smoking cessation and prednisone?
Related Questions
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
How do you determine whether to add abatacept or rituximab to the treatment regimen in patients with mild RA-ILD on methotrexate?
Is there an age at which you consider not starting antifibrotic therapy in a patient with IPF?
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
Would you restart sirolimus for a decline in lung function or pneumothoraces in a pregnant patient with LAM?
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?
What factors do you consider when determining whether to perform a biopsy for the diagnosis of organizing pneumonia?
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
